In-situ biophysical characterization of high-concentration protein formulations using wNMR

References

• Wang SS, Yan YS, Ho K. US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives. Antib Ther. 2021;4(4):262–15. PubMed. doi:10.1093/abt/tbab027.
   PubMedGoogle Scholar
• Bramham JE, Davies SA, Podmore A, Golovanov AP. Stability of a high-concentration monoclonal antibody solution produced by liquid-liquid phase separation. MAbs. 2021;13(1):1940666. From NLM. doi:10.1080/19420862.2021.1940666.
   Web of Science ®Google Scholar
• Roberts CJ. Protein aggregation and its impact on product quality. Curr Opin Biotechnol. 2014;30:211–17. From NLM. doi:10.1016/j.copbio.2014.08.001.
   PubMed Web of Science ®Google Scholar
• Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? J Pharm Sci. 2022;111(4):861–867. doi:10.1016/j.xphs.2021.11.008.
   PubMed Web of Science ®Google Scholar
• Shire SJ. Formulation and manufacturability of biologics. Curr Opin Biotechnol. 2009;20(6):708–14. From NLM. doi:10.1016/j.copbio.2009.10.006.
   PubMed Web of Science ®Google Scholar
• Strickley RG, Lambert WJ. A review of formulations of commercially available antibodies. J Pharm Sci. 2021;110(7):2590–608.e2556. From NLM. doi:10.1016/j.xphs.2021.03.017.
   PubMed Web of Science ®Google Scholar
• Badkar AV, Gandhi RB, Davis SP, LaBarre MJ. Subcutaneous delivery of high-Dose/Volume biologics: Current status and prospect for future advancements. Drug Des Devel Ther. 2021;15:159–70. doi:10.2147/dddt.S287323. From NLM.
   PubMed Web of Science ®Google Scholar
• Bittner B, Richter W, Schmidt J. Subcutaneous Administration of Biotherapeutics: an overview of Current challenges and opportunities. BioDrugs. 2018;32(5):425–40. From NLM. doi: 10.1007/s40259-018-0295-0.
   PubMed Web of Science ®Google Scholar
• Harris RJ, Shire SJ, Winter C. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res. 2004;61(3):137–154. doi:10.1002/ddr.10344.
   Web of Science ®Google Scholar
• Shire JS, G W, Bechthold-Peters K, Andya J. Current trends in monoclonal antibody development and manufacturing. New York: Springer AAPS Press; 2010. doi:10.1007/978-0-387-76643-0.
   Google Scholar
• Warne NW, Mahler HC. Challenges in Protein Product Development. AAPS Adv Pharm Sci Ser. 2018. doi:10.1007/978-3-319-90603-4.
   Google Scholar
• Treuheit MJK, Andrew A, Brems, David N. 2002. Inverse relationship of protein concentration and aggregation. Pharm Res. 19(4):511–16. doi: 10.1023/A:1015108115452.
   Web of Science ®Google Scholar
• Holstein M, Hung J, Feroz H, Ranjan S, Du C, Ghose S, Li ZJ. Strategies for high-concentration drug substance manufacturing to facilitate subcutaneous administration: A review. Biotechnol Bioeng. 2020;117(11):3591–3606. doi:10.1002/bit.27510.
   PubMed Web of Science ®Google Scholar
• Wang W, I AA, Ohtake S, Yang TC, Warne NW, Mahler H-C. Introduction to high-concentration proteins. Challenges in protein product development. AAPS-Springer. 2018;38:99–123.
   Google Scholar
• Yoneda S, Torisu T, Uchiyama S. Development of syringes and vials for delivery of biologics: current challenges and innovative solutions. Expert Opin Drug Deliv. 2021;18(4):459–70. From NLM. doi:10.1080/17425247.2021.1853699.
   PubMed Web of Science ®Google Scholar
• Shire SJ, Shahrokh Z, Liu J. Challenges in the development of high protein concentration formulations. J Pharm Sci. 2004;93(6):1390–1402. doi:10.1002/jps.20079.
   PubMed Web of Science ®Google Scholar
• Scherer TM. Cosolute effects on the Chemical Potential and interactions of an IgG1 monoclonal antibody at high concentrations. J Phys Chem B. 2013;117(8):2254–2266. doi:10.1021/jp3091717.
   Web of Science ®Google Scholar
• Stetefeld J, McKenna SA, Patel TR. Dynamic light scattering: a practical guide and applications in biomedical sciences. Biophys Rev. 2016;8(4):409–27. From NLM. doi: 10.1007/s12551-016-0218-6.
   PubMedGoogle Scholar
• Wang L, Kendrick B, Ma E. Enhanced Protein Structural Characterization Using Microfluidic Modulation Spectroscopy. Spectroscopy. 2018;33:46–52.
   Web of Science ®Google Scholar
• Ivancic VA, Lombardo HL, Ma E, Wikström M, Batabyal D. Advancing secondary structure characterization of monoclonal antibodies using microfluidic modulation spectroscopy. Anal Biochem. 2022;646:114629. doi:10.1016/j.ab.2022.114629.
   Web of Science ®Google Scholar
• Kelly SM, Price NC. The use of circular dichroism in the investigation of protein structure and function. Curr Protein Pept Sci. 2000;1(4):349–84. From NLM. doi:10.2174/1389203003381315.
   PubMed Web of Science ®Google Scholar
• Siligardi G, Hussain R, Patching SG, Phillips-Jones MK. 2014. Ligand- and drug-binding studies of membrane proteins revealed through circular dichroism spectroscopy. Biochimica et Biophysica Acta (BBA) - Biomembr. 1838(1, Part A):34–42. doi: 10.1016/j.bbamem.2013.06.019.
   Web of Science ®Google Scholar
• Wei Y, Wahome N, Kumar P, Whitaker N, Picking WL, Middaugh CR. Effect of phosphate ion on the structure of lumazine synthase, an antigen presentation system from Bacillus anthracis. J Pharm Sci. 2018;107(3):814–823. doi:10.1016/j.xphs.2017.10.013.
   Web of Science ®Google Scholar
• Chennamsetty NV, Vladimir K, Veysel T, Bernhardt L. 2009. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci U S A. 106(29):11937–42. doi: 10.1073/pnas.0904191106.
   PubMed Web of Science ®Google Scholar
• Allec N, Choi M, Yesupriya N, Szychowski B, White MR, Kann MG, Garcin ED, Daniel MC, Badano A. 2015. Small-angle X-ray scattering method to characterize molecular interactions: proof of concept. Sci Rep. 5(1):12085. doi: 10.1038/srep12085.
   Google Scholar
• Altkorn RZ, Richard N. 1984. Effects of saturation on laser-induced fluorescence measurements of population and polarization. Ann Rev Phys Chem. 35(1):265–89. doi: 10.1146/annurev.pc.35.100184.001405.
   Google Scholar
• Winters A, Cheong FC, Odete MA, Lumer J, Ruffner DB, Mishra KI, Grier DG, Philips LA. Quantitative differentiation of protein aggregates from other subvisible particles in viscous mixtures through holographic characterization. J Pharm Sci. 2020;109(8):2405–12. From NLM. doi:10.1016/j.xphs.2020.05.002.
   Web of Science ®Google Scholar
• Demeule B, Messick S, Shire SJ, Liu J. Characterization of particles in protein solutions: reaching the limits of current technologies. AAPS J. 2010;12(4):708–715. doi:10.1208/s12248-010-9233-x.
   PubMed Web of Science ®Google Scholar
• Taraban MB, DePaz RA, Lobo B, Yu YB. 2019. Use of water proton NMR to characterize protein aggregates: gauging the response and sensitivity. Anal Chem. 91(6):4107–4115. doi: 10.1021/acs.analchem.8b05733.
   PubMed Web of Science ®Google Scholar
• Taraban MB, Briggs KT, Yu YB. 2020. Magnetic resonance relaxometry for determination of protein concentration and aggregation. Curr Protoc Protein Sci. 99(1):e102. doi: 10.1002/cpps.102.
   Google Scholar
• Taraban MB, Wang Y, Briggs KT, Yu YB. Inspecting insulin products using water proton NMR. I. Noninvasive vs invasive inspection. J Diabetes Sci Technol. 0(0):19322968211023806. doi:10.1177/19322968211023806.
   Google Scholar
• Taraban MB, DePaz RA, Lobo B, Yu YB. Water proton NMR: a tool for protein aggregation characterization. Anal Chem. 2017;89(10):5494–502. From NLM. doi:10.1021/acs.analchem.7b00464.
   Web of Science ®Google Scholar
• Taraban MB, Truong HC, Feng Y, Jouravleva EV, Anisimov MA, Yu YB. Water proton NMR for in situ detection of insulin aggregates. J Pharm Sci. 2015;104(12):4132–41. From NLM. doi:10.1002/jps.24633.
   Web of Science ®Google Scholar
• Feng Y, Taraban MB, Yu YB. 2015. Water proton NMR—a sensitive probe for solute association. Chem Commun. 51(31):6804–07. doi: 10.1039/C5CC00741K.
   Web of Science ®Google Scholar
• Taraban MB, Truong HC, Ilavsky J, DePaz RA, Lobo B, Yu YB. 2017. Noninvasive detection of nanoparticle clustering by water proton NMR. Transl Mater Res. 4(2):025002. doi: 10.1088/2053-1613/aa7838.
   Google Scholar
• Solomon TL, Delaglio F, Giddens JP, Marino JP, Yu YB, Taraban MB, Brinson RG. Correlated analytical and functional evaluation of higher order structure perturbations from oxidation of NISTmAb. MAbs. 2023;15(1):2160227. doi:10.1080/19420862.2022.2160227.
   PubMed Web of Science ®Google Scholar
• Yu YB, Feng Y, Taraban MB. Water proton NMR for noninvasive chemical analysis and drug product inspection. American Pharma Rev. 2017;20:34–39.
   Google Scholar
• Arbogast LW, Brinson RG, Marino JP. 2015. Mapping monoclonal antibody structure by 2D 13 C NMR at natural abundance. Anal Chem. 87(7):3556–3561. doi: 10.1021/ac504804m.
   Web of Science ®Google Scholar
• Phyo P, Zhao X, Templeton AC, Xu W, Cheung JK, Su Y. 2021. Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy. Adv Drug Deliv Rev. 174:1–29. doi:10.1016/j.addr.2021.02.007.
   Web of Science ®Google Scholar
• Meiboom S, Gill D. Modified spin-echo method for measuring nuclear relaxation times. Rev. Sci. Instr. 1958;29:688–691.
   Web of Science ®Google Scholar
• Kueltzo LA, Wang W, Randolph TW, Carpenter JF. Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. J Pharm Sci. 2008;97(5):1801–12. From NLM. doi:10.1002/jps.21110.
   PubMed Web of Science ®Google Scholar
• Muneeruddin K, Thomas JJ, Salinas PA, Kaltashov IA. Characterization of small protein aggregates and oligomers using size exclusion chromatography with online detection by native electrospray ionization mass spectrometry. Anal Chem. 2014;86(21):10692–99. From NLM. doi:10.1021/ac502590h.
   PubMed Web of Science ®Google Scholar
• Philo JS. Is any measurement method optimal for all aggregate sizes and types? AAPS J. 2006;8(3):E564–71. From NLM. doi: 10.1208/aapsj080365.
   PubMed Web of Science ®Google Scholar
• Ruesch MN, Benetti L, Berkay E, Cirelli DJ, Frantz N, Gastens MH, Kelley WP, Kretsinger J, Lewis M, Novick S, et al. Strategies for setting patient-centric commercial specifications for biotherapeutic products. J Pharm Sci. 2021;110(2):771–784. doi:10.1016/j.xphs.2020.09.048.
   Web of Science ®Google Scholar
• Hills BP, Takacs SF, Belton PS. The effects of proteins on the Proton Nmr Transverse Relaxation-Times of water .1. Native Bovine Serum-Albumin. Mol Phys. 1989;67(4):903–18. doi:10.1080/00268978900101531.
   Web of Science ®Google Scholar
• Briggs KT, Taraban MB, Wang W, Yu YB. Nondestructive quantitative inspection of drug products using benchtop NMR relaxometry-the case of NovoMix® 30. Aaps Pharm Sci Tech. 2019;20(5):189. From NLM. doi:10.1208/s12249-019-1405-0.
   Web of Science ®Google Scholar
• Allmendinger A, Mueller R, Huwyler J, Mahler HC, Fischer S. 2015. Sterile filtration of highly concentrated protein formulations: impact of protein concentration, formulation composition, and filter material. J Pharm Sci. 104(10):3319–3329. doi: 10.1002/jps.24561.
   PubMed Web of Science ®Google Scholar
• Grasso R, Musumeci F, Gulino M, Scordino A, Khodarahmi R. 2018. Exploring the behaviour of water in glycerol solutions by using delayed luminescence. PloS ONE. 13(1):e0191861. doi: 10.1371/journal.pone.0191861.
   Web of Science ®Google Scholar
• Segur JB, Oberstar HE. 1995. Viscosity of glycerol and its aqueous solutions. Ind Eng Chem. 43(9):2117–20. doi: 10.1021/ie50501a040.
   Google Scholar
• Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–75. From NLM. doi: 10.1007/s11095-009-0045-6.
   PubMed Web of Science ®Google Scholar
• Singh SK, Kolhe P, Mehta AP, Chico SC, Lary AL, Huang M. Frozen state storage instability of a monoclonal antibody: aggregation as a consequence of trehalose crystallization and protein unfolding. Pharm Res. 2011;28(4):873–85. From NLM. doi: 10.1007/s11095-010-0343-z.
   PubMed Web of Science ®Google Scholar
• Wu H, Kroe-Barrett R, Singh S, Robinson AS, Roberts CJ. Competing aggregation pathways for monoclonal antibodies. FEBS Lett. 2014;588(6):936–41. From NLM. doi:10.1016/j.febslet.2014.01.051.
   Web of Science ®Google Scholar
• Banks DD, Latypov RF, Ketchem RR, Woodard J, Scavezze JL, Siska CC, Razinkov VI. Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies. J Pharm Sci. 2012;101(8):2720–32. From NLM. doi:10.1002/jps.23219.
   PubMed Web of Science ®Google Scholar
• Roberts CJ. Non-native protein aggregation kinetics. Biotechnol Bioeng. 2007;98(5):927–38. From NLM. doi:10.1002/bit.21627.
   PubMed Web of Science ®Google Scholar
• Caflisch A. Computational models for the prediction of polypeptide aggregation propensity. Curr Opin Chem Biol. 2006;10(5):437–44. From NLM. doi:10.1016/j.cbpa.2006.07.009.
   Web of Science ®Google Scholar
• Bou-Abdallah F, Terpstra TR. The thermodynamic and binding properties of the transferrins as studied by isothermal titration calorimetry. Biochim Biophys Acta. 2012;1820(3):318–25. From NLM. doi:10.1016/j.bbagen.2011.07.013.
   Web of Science ®Google Scholar
• McPherson A, Gavira JA. Introduction to protein crystallization. Acta Crystallogr F Struct Biol Commun. 2014;70(1):2–20. From NLM. doi: 10.1107/s2053230x13033141.
   Google Scholar
• Heller MC, Carpenter JF, Randolph TW. Protein formulation and lyophilization cycle design: prevention of damage due to freeze-concentration induced phase separation. Biotechnol Bioeng. 1999;63(2):166–74. acccessed 2022/10/20. doi:10.1002/(SICI)1097-0290(19990420)63:2<166:AID-BIT5>3.0.CO;2-H.
   PubMed Web of Science ®Google Scholar
• Mirasol F. Stability testing of protein therapeutics using DLS. BioPharm International, BioPharm International. 2021;34:41–43.
   Web of Science ®Google Scholar
• Esfandiary R, Parupudi A, Casas-Finet J, Gadre D, Sathish H. Mechanism of reversible self-association of a monoclonal antibody: role of electrostatic and hydrophobic interactions. J Pharm Sci. 2015;104(2):577–586. doi:10.1002/jps.24237.
   Web of Science ®Google Scholar
• Fekete S, Beck A, Veuthey JL, Guillarme D. Theory and practice of size exclusion chromatography for the analysis of protein aggregates. J Pharm Biomed Anal. 2014;101:161–73. doi:10.1016/j.jpba.2014.04.011. From NLM.
   PubMed Web of Science ®Google Scholar
• Hong P, Koza S, Bouvier ES. Size-exclusion chromatography for the Analysis of Protein Biotherapeutics and their aggregates. J Liq Chromatogr Relat Technol. 2012;35(20):2923–50. From NLM. doi:10.1080/10826076.2012.743724.
   PubMed Web of Science ®Google Scholar
• Liu J, Nguyen MD, Andya JD, Shire SJ. Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution. J Pharm Sci. 2005;94(9):1928–40. From NLM. doi:10.1002/jps.20347.
   PubMed Web of Science ®Google Scholar
• Sharma DK, King D, Oma P, Merchant C. Micro-flow imaging: flow microscopy applied to sub-visible particulate analysis in protein formulations. AAPS J. 2010;12(3):455–64. From NLM. doi: 10.1208/s12248-010-9205-1.
   Web of Science ®Google Scholar
• Taraban MB, Wang Y, Briggs KT, Yu YB. Inspecting insulin products using water proton NMR. I. Noninvasive vs invasive inspection. J Diabetes Sci Technol. 2021:19322968211023806. From NLM. doi:10.1177/19322968211023806.
   Google Scholar
• Jiang M, Severson KA, Love JC, Madden H, Swann P, Zang L, Braatz RD. Opportunities and challenges of real-time release testing in biopharmaceutical manufacturing. Biotechnol Bioeng. 2017;114(11):2445–56. From NLM. doi:10.1002/bit.26383.
   Web of Science ®Google Scholar
• Kaur H, Beckman J, Zhang Y, Li ZJ, Szigeti M, Guttman A. Capillary electrophoresis and the biopharmaceutical industry: therapeutic protein analysis and characterization. TrAC Trend Anal Chem. 2021;144:116407. doi:10.1016/j.trac.2021.116407.
   Web of Science ®Google Scholar
• Challener CA. Tackling the challenge of HOS determination. BioPharm International. 2014;27(2):20–24.
   Web of Science ®Google Scholar
• Liu J, Andya JD, Shire SJ. A critical review of analytical ultracentrifugation and field flow fractionation methods for measuring protein aggregation. AAPS J. 2006;8(3):E580–89. From NLM. doi: 10.1208/aapsj080367.
   PubMed Web of Science ®Google Scholar
• Giddings JC. Field-flow fractio nation: analysis of macromolecular, colloidal, and particulate materials. Sci. 1993;260(5113):1456–65. From NLM. doi: 10.1126/science.8502990.
   Web of Science ®Google Scholar
• Briggs KT, Taraban MB, Yu YB. Quality assurance at the point-of-care: noninvasively detecting vaccine freezing variability using water proton NMR. Vaccine. 2020;38(31):4853–4860. doi:10.1016/j.vaccine.2020.05.049.
   PubMed Web of Science ®Google Scholar
• Bruce Yu Y, Taraban MB, Briggs KT. All vials are not the same: potential role of vaccine quality in vaccine adverse reactions. Vaccine. 2021;39(45):6565–69. From NLM. doi: 10.1016/j.vaccine.2021.09.065.
   Web of Science ®Google Scholar
• Yu YB, Taraban MB, Wang W, Briggs KT. Improving biopharmaceutical safety through Verification-Based Quality Control. Trends Biotechnol. 2017;35(12):1140–55. From NLM. doi:10.1016/j.tibtech.2017.08.010.
   Web of Science ®Google Scholar
• Yu LX, Kopcha M. The future of pharmaceutical quality and the path to get there. Int J Pharm. 2017;528(1–2):354–59. From NLM. doi:10.1016/j.ijpharm.2017.06.039.
   PubMedGoogle Scholar
• Telikepalli SN, Kumru OS, Kalonia C, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J Pharm Sci. 2014;103(3):796–809. From NLM. doi:10.1002/jps.23839.
   PubMed Web of Science ®Google Scholar
• Yu YB, Briggs KT, Taraban MB, Brinson RG, Marino JP. Grand Challenges in pharmaceutical research series: ridding the cold chain for biologics. Pharm Res. 2021;38(1):3–7. From NLM. doi: 10.1007/s11095-021-03008-w.
   PubMed Web of Science ®Google Scholar
• Rosenberg AS, Verthelyi D, Cherney BW. Managing uncertainty: a perspective on risk pertaining to product quality attributes as they bear on immunogenicity of therapeutic proteins. J Pharm Sci. 2012;101(10):3560–67. From NLM. doi:10.1002/jps.23244.
   Web of Science ®Google Scholar
• Yu YB, Briggs KT, Taraban MB. Preventive pharmacovigilance: timely and precise prevention of adverse events through person-level patient screening and dose-level product surveillance. Pharm Res. 2023. doi:10.1007/s11095-023-03548-3.
   Web of Science ®Google Scholar
• Chen K, Cheung JK, Kim HY, Leone A, Mallela K, Su YC. 2023. Enabling efficient design of biological formulations through advanced characterizations. Pharm Res. 40(6):1313–16. doi: 10.1007/s11095-023-03557-2.
   Web of Science ®Google Scholar
• Li M, Falk BT, Lu X, Schroder R, McCoy M, Xu W, Yin DH, Gindy ME, D’Addio SM, Su Y. 2022. Molecular Mechanism of Antimicrobial Excipient-Induced Aggregation in Parenteral Formulations of Peptide Therapeutics. Mol Pharm. 19(9):3267–3278. doi: 10.1021/acs.molpharmaceut.2c00449.
   Google Scholar
• Li M, Reichert P, Narasimhan C, Sorman B, Xu W, Cote A, Su Y. 2022. Investigating Crystalline Protein Suspension Formulations of Pembrolizumab from MAS NMR Spectroscopy. Mol Pharm. 19(3):936–952. doi: 10.1021/acs.molpharmaceut.1c00915.
   Google Scholar
• Li M, Koranne S, Fang R, Lu X, Williams DM, Munson EJ, Bhambhani A, Su Y. 2021. Probing Microenvironmental Acidity in Lyophilized Protein and Vaccine Formulations Using Solid-state NMR Spectroscopy. J Pharm Sci. 110(3):1292–1301. doi: 10.1016/j.xphs.2020.11.017.
   Web of Science ®Google Scholar
• Du Y, Li J, Xu W, Cote A, Lay-Fortenbery A, Suryanarayanan R, Su Y. 2023. Solid-State NMR Spectroscopy to Probe State and Phase Transitions in Frozen Solutions. Mol Pharm. 20(12):6380–6390. doi: 10.1021/acs.molpharmaceut.3c00764.
   Google Scholar
• Chen Y, Ling J, Li M, Su Y, Arte KS, Mutukuri TT, Taylor LS, Munson EJ, Topp EM, Zhou QT. 2021. Understanding the impact of protein-excipient interactions on physical stability of spray-dried protein solids. Mol Pharm. 18(7):2657–68. doi: 10.1021/acs.molpharmaceut.1c00189.
   Google Scholar
• Mutukuri TT, Ling J, Du Y, Su Y, Zhou QT. Effect of Buffer salts on physical stability of lyophilized and spray-dried protein formulations containing bovine serum albumin and trehalose. Pharm Res. 2023;40(6):1355–1371. doi:10.1007/s11095-022-03318-7.
   Web of Science ®Google Scholar